Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization
- PMID: 27982020
- DOI: 10.1038/cgt.2016.76
Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization
Abstract
Angiogenesis is among the most important mechanisms that helps cancer cells to survive, grow and undergo metastasis. Therefore, inhibiting angiogenesis will suppress tumor growth. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are believed to be important players of angiogenesis. The goal of this study was to evaluate the success of a novel nanobody against VEGFR2 in tethering its target inside the endoplasmic reticulum and preventing its transport to the cell membrane. Nanobody sequence was cloned in a mammalian vector in fusion with green fluorescent protein and a KDEL retention signal. After transfection of 293KDR cells with this expression vector, surface localization of VEGFR2 was monitored by flow cytometry. This study demonstrates that our intrananobody is effective in targeting VEGFR2 receptor, and therefore, it is a powerful tool to downregulate a surface-exposed target protein, and in this capacity, it has potential to be used as a therapeutic protein to inhibit growth of tumors.
Similar articles
-
Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR).J Immunol Methods. 2005 May;300(1-2):146-59. doi: 10.1016/j.jim.2005.03.007. J Immunol Methods. 2005. PMID: 15946674
-
Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis.FASEB J. 2003 Sep;17(12):1733-5. doi: 10.1096/fj.02-0942fje. Epub 2003 Jul 3. FASEB J. 2003. PMID: 12958192
-
Generation and characterization of a human nanobody against VEGFR-2.Acta Pharmacol Sin. 2016 Jun;37(6):857-64. doi: 10.1038/aps.2016.2. Epub 2016 Apr 25. Acta Pharmacol Sin. 2016. PMID: 27108602 Free PMC article.
-
Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature.Mol Biotechnol. 2016 Nov;58(11):738-747. doi: 10.1007/s12033-016-9973-7. Mol Biotechnol. 2016. PMID: 27647452
-
Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell.Protein Expr Purif. 2016 Jul;123:19-25. doi: 10.1016/j.pep.2016.03.004. Epub 2016 Mar 17. Protein Expr Purif. 2016. PMID: 26996993
Cited by
-
Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies.Cancer Chemother Pharmacol. 2022 Feb;89(2):165-172. doi: 10.1007/s00280-021-04372-5. Epub 2022 Jan 6. Cancer Chemother Pharmacol. 2022. PMID: 34988654
-
VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo.Cancer Biol Med. 2021 Apr 8;18(3):772-87. doi: 10.20892/j.issn.2095-3941.2020.0568. Cancer Biol Med. 2021. PMID: 33830713 Free PMC article.
-
Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate.Iran J Basic Med Sci. 2022 Mar;25(3):313-319. doi: 10.22038/IJBMS.2022.62522.13834. Iran J Basic Med Sci. 2022. PMID: 35656179 Free PMC article.
-
Antiangiogenic effects of oridonin.BMC Complement Altern Med. 2017 Apr 4;17(1):192. doi: 10.1186/s12906-017-1706-3. BMC Complement Altern Med. 2017. PMID: 28376864 Free PMC article.
-
Cell-specific targeting by engineered M13 bacteriophage expressing VEGFR2 nanobody.Iran J Basic Med Sci. 2018 Sep;21(9):884-888. doi: 10.22038/IJBMS.2018.26191.6432. Iran J Basic Med Sci. 2018. PMID: 30524687 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources